Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $23.96, up 4.90%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CPRX shares have gain 4.77% over the last week, with a monthly amount glided 9.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on November 18, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $35. Previously, Citigroup started tracking the stock with Buy rating on March 14, 2024, and set its price target to $27. On March 07, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $23 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $30 on December 21, 2023. ROTH Capital downgraded its rating to a Neutral and raised its price target to $15.50 on August 24, 2022.
Catalyst Pharmaceuticals Inc [CPRX] stock has fluctuated between $13.12 and $24.27 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $23.96 at the most recent close of the market. An investor can expect a potential return of 46.08% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] reported sales of 460.48M for the trailing twelve months, which represents a growth of 25.33%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.38%, Pretax Profit Margin comes in at 0.41%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.26 and Total Capital is 0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.12 points at the first support level, and at 22.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.52, and for the 2nd resistance point, it is at 25.08.
Ratios To Look Out For
For context, Catalyst Pharmaceuticals Inc’s Current Ratio is 5.11. Further, the Quick Ratio stands at 4.92, while the Cash Ratio is 4.2. Considering the valuation of this stock, the price to sales ratio is 6.21, the price to book ratio is 4.32 and price to earnings (TTM) ratio is 20.44.
Transactions by insiders
Recent insider trading involved Miller Steve, Chief Op. & Scientific Officer, that happened on Dec 10 ’24 when 50000.0 shares were sold. Officer, Miller Steve completed a deal on Dec 10 ’24 to buy 50000.0 shares. Meanwhile, Chief Med. & Reg. Officer INGENITO GARY sold 12000.0 shares on Nov 27 ’24.
